DMD is discussed in detail as a paradigm illustrating diagnosis, management and role for different pharmacological interventions to improve survival, but also challenges in adulthood care, and cutting edge therapies.
Introduction
The muscular dystrophies are an inherited group of disorders characterised by muscle wasting and weakness, and sharing common histological features of "dystrophic" muscle biopsy changes, including variation in muscle fibre size, muscle fibre degeneration and regeneration, and replacement of muscle by connective tissue and fat. The clinical and genetic heterogeneity of these conditions is well recognised: some have prenatal onset while others only affect adults, some are rapidly progressive, while others are associated with prolong periods of stability; some are associated with multisystem involvement including cardiac and central nervous system. The major Introduction DMD is the most frequent muscular dystrophy variant, affecting 1 in every 3,500 live male births. Common presentation is with abnormal gait, calf hypertrophy and difficulty in rising from the floor between 2 to 5 years of age; speech / global developmental delay may dominate the presentation in a minority of cases. 1 2 Untreated, progression of muscle weakness leads to complete wheelchair dependence by the thirteenth birthday, followed by scoliosis, respiratory insufficiency, cardiomyopathy and death in the late teens or early twenties. Feeding difficulties and weight loss are common in the late stages of the disease.
Though a curative treatment is not yet available, the multidisciplinary team (MDT) proactive approach 3 for optimal surveillance and management of multisystem complications together with pharmacological intervention with corticosteroids has altered the natural history of DMD, so that most of these individuals can now be anticipated to survive into adulthood, with transfer of care to the adult neurologists.
Genetics and Pathophysiology
A brief review of the molecular genetic basis of DMD is essential to understand the approach to diagnosis and limitations of the various diagnostic techniques. DMD is caused by mutations in the Dystrophin gene at Xp21. The dystrophin locus contains 85 exons and encodes for a large but low abundance protein, named dystrophin. 4 Dystrophin is a rod shaped protein, which localises at the cytoplasmic side of the sarcolemma: the carboxyl terminal end binds to the dystrophin associated glycoprotein complex at the sarcolemma while the amino terminal end binds to the cytoskeletal actin.
Dystrophin is postulated to be essential for protection of the sarcolemma from DMD is a X-linked recessive condition, but there is a high incidence of new mutations and at least 1/3 of the cases do not have a positive family history.
Diagnosis
The characteristic phenotype of a boy under five with calf hypertrophy, toe / waddling gait and Gowers' sign lends to easy recognition. Global developmental delay is the other frequent early presentation. Serum Creatine Kinase (CK) is massively elevated (10-100x normal, since birth) and should be the first investigation when DMD is suspected.
Electromyography (EMG) has no role in the investigation of DMD and should not be requested.
The advances in molecular genetic testing over the last decade have vastly improved mutation detection in the dystrophin gene. As most DMD patients carry deletions in two mutational hot spots of the gene, the screening of only 19 exons, following amplification of genomic DNA, was the mainstay of the diagnosis until recently as it allowed to identify mutations in ~ 65% of cases. 5 The limitations of this technique include the inability to identify rarer mutations and the breakpoints of some deletions. Other genomic DNA based techniques such as multiplex ligation dependent probe amplification 6 method, or a combinatorial strategy using the fluorescent multiplex quantitative PCR followed by conformation sensitive capillary electrophoresis (CSCE), 7 have increased the efficiency of mutation detection close to 100%. Another major advantage of these techniques is their ability to detect mutations in carrier females, allowing a precise genetic counselling.
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The molecular genetic documentation of a dystrophin mutation alone allows to predict accurately the phenotype in ~ 90% of cases, while exceptions to the frame shift hypothesis account for 10% of cases. Establishing the precise diagnosis of DMD, especially in young and not fully collaborative children, is therefore best achieved by a combination of clinical observation of the patient's strength and functional abilities, ascertainment of dystrophin levels on muscle biopsy and knowledge of the gene mutation.
A partial dystrophin deficiency is the hallmark of BMD; it is important to recognise that secondary dystrophin protein reduction may occur in LGMDs due to mutations in sarcoglycan genes or, more rarely, in genes responsible for α -dystroglycanopathies. 8 Western blot analysis is helpful in such cases as the identification of a truncated protein product clearly points towards the primary gene defect, as in BMD.
Management

Physiotherapy and orthoses
Physiotherapy to prevent joint deformities and promote walking remains important 9 and these principles are applicable to other LGMDs as well. In DMD, rehabilitation in knee ankle foot orthoses (KAFOs) at the time of loss of independent walking is effective in prolonging walking for an average of 18 months to two years. This has been associated with reduced incidence of scoliosis. 10 
Glucocorticoid corticosteroids
A recent Cochrane systematic review of the glucocorticoids in DMD is available. 11 In randomised controlled trials (RCT), prednisone stabilised strength and function for 6 months to 2 years. Non-randomised studies with daily dose Prednisone (0.75mg/kg) or deflazacort (0.9 mg/kg), have documented prolongation of walking ability, preservation of respiratory function and reduction in the incidence of scoliosis and cardiomyopathy 16 There is currently no evidence that oral bisphosphonates should be used prophylactically in children receiving steroids; however their acute administration is recommended in the treatment of vertebral fractures, where they are very effective.
Management of respiratory complications
Decreasing respiratory reserve in the teenage years leads to sleep disordered breathing, with REM sleep related hypoxemic dips 17 and obstructive apnoeas.
The resulting symptoms include morning drowsiness, poor appetite, headaches, nausea, fatigue, tiredness, poor concentration at school, failure to thrive, reduced coughing ability or overt respiratory failure in the course of "minor" respiratory infections.
In the past, the onset of symptomatic sleep hypoventilation signified imminent demise, as the only way to prolong life was mechanical ventilation through Forced vital capacity (FVC) predicts the development of hypercapnia and survival. 21 Regular monitoring for symptoms of sleep hypoventilation, FVC, and overnight sleep studies when the FVC falls below 50% allow for timely intervention with NIV. Gradual initiation of NIV in the phase of nocturnal hypercapnia but daytime normocapnia, 22 without waiting for daytime ventilatory failure, allows the individual to acclimatise to the ventilator and avoids uncontrolled decompensation during chest infections.
Management of cardiac complications
Dilated cardiomyopathy (DCM) occurs in up to 90% of DMD individuals
years. The severity varies and traditionally, cardiomyopathy was considered responsible for death in up to 20% of DMD individuals. This proportion is likely to increase over the coming years as NIV prevents respiratory related mortality. There is some controversy regarding optimal timing of introduction of therapy for DCM. 23 Duboc et al reported that early treatment with the Angiotensin converting enzyme (ACE) inhibitor perindopril delayed the onset and progression of prominent LV dysfunction, and was associated with lower mortality in DMD. 24 Some cardiologists suggest that treatment is not necessary for a complication that is often asymptomatic for a long time before deteriorating into clear-cut cardiac failure 23 , though this view is at odds with the current evidence on related forms of DCM, in which early treatment is clearly superior compared to late therapy. Indeed considering the invariable occurrence of DCM in DMD, intervention before progression to severe cardiomyopathy would be logical.
While awaiting the results of RCT, the published consensus documents 25 recommend the use of ACE inhibitors and beta blockers in patients with early cardiomyopathy. It is important to look for and treat co-existing nocturnal hypoventilation, which aggravates cardiac function.
Scoliosis management
Scoliosis usually develops in the phase of constant wheel chair dependence,
shows rapid progression during pubertal growth spurt and adversely affects respiratory function, feeding, seating and comfort.
Progression of the spinal curve is the indication for surgical spinal fusion. 26 The optimum time for making the decision is when the range of the curve's
Cobb angle is 20 0 -40 0 . MDT input is essential to ensure that the operation is performed at a time when the FVC is above 30% predicted for height, and the cardiac function, as confirmed by echocardiogram, is good. Spinal surgery can be performed when the FVC is below 30%, but the risks are greater, and is best undertaken in specialized centres. 27 Spinal brace (jacket) does not prevent progression of scoliosis, but may be useful in postural management, especially in cases where spinal surgery is contraindicated or not acceptable to the patient.
Nutritional aspects
These include obesity during the late ambulant phase, especially in corticosteroid treated individuals, and severe wasting in the spinal surgery post-operative period and the late teenage years. Regular weight monitoring and dietary advice to avoid obesity should be offered to all DMD patients, especially when treated with daily corticosteroids.
Young adults with DMD may have chewing and swallowing difficulties, 28 prolonged mealtimes; episodes of choking on food contribute to fear of eating and failure to thrive, although frank aspiration is very rare. Appropriate facilities for hoisting and weighing the wheel chair dependent adolescents should be available in the clinics to facilitate regular weight monitoring.
Patients with failure to thrive and/or dysphagia benefit by dietetic and speech and language therapist's assessment for nutritional supplementation and advice about postural management, feeding aids or gastrostomy insertion.
Survival, new complications and transition of care
Eagle et al 19 
Genetic therapies for DMD
Research aimed at finding a genetic based treatment has been greatly facilitated by the use of two naturally occurring animal models; the dystrophic golden retriever dog (GRMD), which suffers a fatal clinical course akin to the humans and the mdx mouse which has a stop codon in exon 23 resulting in dystrophin deficiency but no overt weakness or reduced life span. The various genetic strategies aimed at restoration of dystrophin in the affected muscle 33 are listed with a basic description and their current status in table 1. These models have allowed two strategies to be firstly developed as proof of concept, and more recently to be experimented in human subjects, as discussed below.
Exon skipping with antisense oligonucleotides:
The strategy behind the use of antisense oligonucleotides (AOs, also known as "molecular patches") is the modification of dystrophin mRNA splicing.
These small RNA-like molecules prevent the normal splicing of the gene by The study of the MDEX consortium demonstrated that the intramuscular administration of a morpholino AO (AVI-4658) was safe; the same antisense oligonucleotide will now be studied in an intravenous dose ranging study with 12 weekly infusions.
Read-through of stop codon mutations
This technique is applicable to ~10% of DMD patients, those carrying dystrophin gene nonsense point mutations, 36 causing premature cessation of translation.
Aminoglycosides cause misreading of the RNA code at the premature but not the normal termination codons, leading to insertion of alternative amino acids at the site of the mutated codon, transcription and protein formation. Gentamicin was effective in the mdx mice, 37 but the results were not replicated in a human trial of intravenous gentamicin in 2 DMD and 2 BMD subjects.
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PTC124 is an orally administered investigational compound which allows read through at the nonsense mutations, and showed an acceptable safety profile in 62 healthy adult volunteers in phase 1study. 39 A multinational multicentre RCT of PTC124 is currently underway (http://clinicaltrials.gov/ct2/show/NCT00592553).
Becker Muscular Dystrophy (BMD)
The incidence is about one-fifth of that for DMD and the prevalence 40 in the male population around 14 x 10 6 . Of interest is the heterogeneity of the presentation including typical hypertrophic, proximal weakness BMD, quadriceps myopathy, X-linked cramps, myoglobinuria, and isolated cardiomyopathy. Cardiomyopathy occurs in up to 72% of BMD patients, 41 and is the determinant of survival in this condition. Rarely, hitherto undiagnosed BMD patients with no/mild weakness may first present with a potentially fatal "malignant hyperthermia like" reaction with rhabdomyolysis, hyperkalemia and myoglobinuria 42 on exposure to suxamethonium or halogenated inhaled anaesthetic for a surgical procedure. This rhabdomyolytic risk is common to DMD and BMD, and a notable caution in their anaesthetic management. 43 Kesari et al 44 reported a higher rate of exceptions to the reading frame in
Becker muscular dystrophy, partly explained by a high incidence of deletions in 5′ of the dystrophin gene (a region known for hotspots for exceptions), and due to alternative splicing patterns.
A higher incidence of learning difficulties, behavioural problems, and autistic spectrum disorders has been reported in BMD as compared to the general population.
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Manifesting Carriers of DMD / BMD
Approximately 2-5% of female carriers of the mutated dystrophin gene, may have skeletal muscle symptoms and are described as manifesting carriers.
Their symptoms range from muscle pain & cramps on exertion to a proximal girdle weakness, which rarely can be severe enough to cause wheelchair dependence. 46 Female carriers of Duchenne muscular dystrophy have a 10% lifetime risk of developing cardiomyopathy; apart from genetic counselling and antenatal diagnosis, this is a key reason for precise evaluation of the carrier status to institute echocardiograhic surveillance and treatment if necessary.
The possibility of carrier of DMD/BMD should be considered in the differential diagnosis of asymptomatic serum CK elevation and/or muscle weakness in females, as it is an important differential diagnosis for LGMD.
Carriers of DMD dystrophy may show a mosaic pattern of dystrophin positive and dystrophin negative fibres 8 (reduced dystrophin in BMD carriers) on muscle immunocytochemistry. It is important to note that a minority of carriers may have normal dystrophin immunostaining on muscle biopsy, 47 and dystrophin gene analysis should be performed for all suspected carriers.
Limb-Girdle Muscular Dystrophy (LGMD)
Detailed reviews of LGMD classification, phenotypes, pathogenesis, genetic basis and management are available. 48 -53 This review highlights the common phenotypes, specific features associated with some of the LGMDs, providing The overall frequency of LGMD is 1 in 15,000 40 . The variable incidence of
LGMD subtypes in specific population/country is well recognised, and may help direct investigations in a particular patient. An example is the LGMD2I, which is the commonest muscular dystrophy in some Northern European countries as compared to a higher incidence of sarcoglycanopathy in Northern Africa, and LGMD2B and LGMD2A in an Australian cohort. 54 The diversity of the clinical features, the genetic heterogeneity, and the lack of easily available DNA based molecular genetic testing emphasises the need for a methodical approach, based on the clinical features of the individual patient, to prioritise investigations and molecular genetic diagnosis.
Serum CK level may be a pointer to certain LGMD subtypes, but it is not an absolute screening test for all LGMDs, as it may rarely be normal (eg 
LGMD1B (Laminopathy)
This is an allelic variant of the autosomal dominant form of Emery Dreifuss muscular dystrophy (EDMD), a form characterised by predominant scapulohumeral wasting and elbow and Achilles tendon contractures. 55 The defective gene is the LMNA; when mutated most patients present with typical EDMD features, but a minority show more proximal weakness, and absence of prominent contractures, featuring the LGMD1B phenotype. As in EDMD,
LGMD1B patients have a high incidence of cardiac involvement. Mutations in LMNA however can give rise to a much wider spectrum of clinical phenotypes, ranging from children presenting in the first year of life within features evocative of a congenital muscular dystrophy 58 to isolated cardiac complications. There is a high incidence of de-novo dominant mutations.
Experts' guidance 25 on surveillance and management of the life threatening the cardiac complications, especially the ventricular dysrrythmias, which can lead to sudden death despite pacing, are available. Recently these advocate the use of defibrillators, and not pace-makers, in individuals with laminopathies.
LGMD1C (Caveolinopathy)
In a series of 10 patients, Aboumousa et al 59 reported myalgia as a prominent symptom symptoms of caveolinopathy; this adds to the recognised broad spectrum of presentation including LGMD1C, distal myopathy, rippling muscle disease, and HyperCKemia. Rippling in muscle is present in majority of
LGMD1C phenotype patients.
LGMD2A (Calpainopathy):
LGMD2A, one of the most prevalent LGMD, is caused by mutations in calpain-3 gene (CAPN3), coding for an enzyme calpain 3, which binds together different proteins involved in myofibrillogenesis. 60 The characteristic LGMD phenotype is remarkable for marked involvement of posterior thigh muscles (well visible also on muscle MRI 61 ), tendo-Achilles contractures and scapular winging, and high CK, but the phenotypic variability is wide. The immunoblot analysis of calpain 3 was considered the mainstay of the diagnostic process but more recently normal protein expression on blot has been reported for a significant proportion of cases, suggesting that an apparently normal western blot does not reliably rule out LGMD2A. 62 63 Additionally, a secondary deficiency of calpain 3 has been described in several muscular dystrophies, including LGMD2B (dysferlinopathy). Final diagnosis therefore rests on CAPN3 gene mutation confirmation.
Muscle MRI in LGMD2A 61 shows characteristic and early involvement of adductors, semimembranosus, and vastus intermediate muscles in the thigh, and these observations may help direct CAPN 3 molecular genetic studies.
LGMD2B (Dysferlinopathy):
The characteristic phenotype is of presentation in late teenage years, with reduction of previous good motor abilities, with markedly high serum CK. 64 The early gastrocnemius weakness, with inability to stand on toes is a valuable clinical clue. There may be a phenotypic overlap with allelic Miyoshi myopathy (MM). The diagnosis is reliant on muscle immunoblotting study, and ultimately, the gene study 65 .
Currently, a double blind, placebo-controlled study Deflazacort in
LGMD2B/MM) is in progress in Munich (www.clinicaltrials.gov).
LGMD2D (α-sarcoglycanopathy)
LGMD2D 66 is the most frequent sarcoglycanopathy; these are four conditions due to the deficiency of one of the 4 sarcoglycan (SG) proteins (α,β,γ,δ SG, LGMD2I (FKRP related
This is one of the commonest forms of LGMD in Northern Europe.
Phenotypic similarity with DMD or BMD 70 can be striking and many sporadic cases of this condition were misdiagnosed as a dystrophinopathy in the past. 71 Cardiac 72 and respiratory involvement is common. The common missense mutation (L2761) is frequently associated with milder severity, and helps expedite molecular genetic diagnosis.
LGMD2I is the most common of the "α-dystroglycanopathies," which are LGMD2J (Titinopathy)
Titin is a sarcomeric protein connecting the Z-disk with the M-line, and considered to contribute to striated muscle development, structure, elasticity, and cell signalling. Tibial muscular dystrophy (TMD), described by Udd 79 in
Finland, is the most common allelic phenotype, and is secondary to heterozygous dominant mutation in C terminus exons of the TTN gene.
LGMD2J is the earlier onset, more severe phenotype of homozygous distal 
Conclusion
With the improved survival of patients with muscular dystrophies, DMD in particular, it is anticipated there will be an increased caseload for the adult neurologist, and calls for a proactive approach in management. The MDT management model for DMD lends well to adult neuromuscular practice for
LGMDs with disease progression and multisystem involvement, and allows disease specific monitoring and management protocols to improve survival.
The current sub-optimal social support for these patients with disability and complex needs has to be rectified to augment patient and carer's of quality of life.
The patient-lead drives to find curative treatments in DMD and LGMD are now stronger than ever, and require a cohesive approach for integration of clinical and research teams to enable precise diagnosis and translational research. Table 2 . Muscular dystrophies presenting with limb girdle distribution of weakness, and some of their allelic variant phenotypes.
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